Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed as antidiabetic agents, have emerged as candidate disease-modifying therapies for Parkinson’s disease (PD) and Alzheimer’s disease (AD), reflecting the widespread expression of GLP-1 receptors across neurons, glia, and the cerebral vasculature. This narrative review synthesizes mechanistic, clinical trial, and biomarker evidence for GLP-1 RAs in PD and AD, based on a literature search of PubMed, Embase, Scopus, and Web of Science, with ClinicalTrials.gov searched separately for trial protocols and results, through May 2026. Preclinical data implicate GLP-1 receptor agonism in anti-neuroinflammatory signaling, mitochondrial preservation, autophagy and proteostasis enhancement, anti-apoptotic effects, synaptic plasticity, cerebrovascular protection, and glymphatic clearance. Clinical evidence in PD is mixed and agent- and formulation-dependent: the phase II Exenatide-PD trial reported a motor benefit that persisted after washout (∼3.5-point between-group difference in MDS-UPDRS Part III), and the phase II LIXIPARK trial (lixisenatide) reported a significant 3.08-point between-group difference (95% CI 0.86–5.30; p = 0.007) favoring lixisenatide, whereas the larger, longer phase III Exenatide-PD3 trial, using an extended-release weekly formulation, found no significant effect on the same endpoint (adjusted coefficient 0.92; 95% CI −1.56 to 3.39; p = 0.47); oral semaglutide is under investigation in the ongoing phase II MOST-ABLE trial. In AD, the phase IIb liraglutide (ELAD) trial did not achieve statistical benefit on either its primary imaging endpoint (cerebral glucose metabolic rate; p = 0.14) or on most secondary cognitive measures, and the phase III semaglutide trials EVOKE and EVOKE+ did not meet their primary CDR-SB endpoint (estimated difference −0.08, 95% CI −0.35 to 0.20, p = 0.57 in EVOKE; 0.10, 95% CI −0.17 to 0.38, p = 0.46 in EVOKE+), despite biomarker signals including reductions in cerebrospinal fluid tau species and inflammatory markers. Comparative pharmacology reveals substantial heterogeneity in central nervous system penetration, receptor engagement, and systemic bioavailability across exenatide, liraglutide, semaglutide, and the imbalanced GLP-1/GIP co-agonist tirzepatide, complicating cross-agent extrapolation. Persistent challenges include separating direct neuroprotection from indirect metabolic and cardiovascular benefit, limited characterization of brain drug exposure, trial durations that may be short relative to the expected latency of a disease-modifying effect, and the absence of validated response biomarkers. We conclude that although the mechanistic and epidemiological rationale for GLP-1 RAs in neurodegeneration remains biologically plausible, current trial evidence does not yet support their use outside clinical trials, irrespective of comorbid diabetes status; future studies should prioritize earlier intervention, biomarker-guided patient selection, adequately powered subgroup analyses, and brain-penetrant formulations.
Background/Objectives: Children with Down syndrome are at increased risk of obstructive sleep apnea (OSA), which cannot be reliably excluded by symptoms or examination. Saudi evidence remains limited. This review synthesizes international and Saudi evidence and proposes a pediatric care pathway incorporating the transition to adult services. Methods: We conducted a structured narrative review of the English-language literature identified through PubMed/MEDLINE, selected journal websites, and reference lists. The review focused on publications from January 2018 to 17 September 2026, retaining relevant earlier studies. Evidence was synthesized qualitatively without a new meta-analysis or formal risk of bias assessment. Results: Published international estimates indicate that OSA affects approximately 50–79% of children with Down syndrome. American Academy of Pediatrics guidance recommends polysomnography (PSG) at ages 3–4 years regardless of symptoms, with earlier assessment when indicated. Nonrandomized infant intervention studies suggest potential benefits but do not establish an optimal universal screening schedule. Saudi evidence includes a small earlier PSG referral cohort and more recent caregiver surveys; no nationally representative PSG-confirmed prevalence study was identified. Arabic questionnaire validation in a mixed pediatric referral cohort does not establish Down syndrome-specific diagnostic accuracy. Published treatment evidence indicates that adenotonsillectomy often improves OSA, although residual disease commonly requires objective reassessment and individualized management. Conclusions: The evidence supports age-based PSG, earlier assessment when indicated, postoperative reassessment, and individualized multidisciplinary care. Building on this evidence, we propose a Saudi pathway linking referral tracking, family-centered positive airway pressure support, and coordinated transition. Regional networks and registry development remain unevaluated implementation proposals requiring stakeholder consultation, resource assessment, and pilot testing; they do not constitute an endorsed national guideline.
Down syndromeobstructive sleep apneasleep-disordered breathingpolysomnography screening
Protracted bacterial bronchitis (PBB) is a treatable cause of chronic wet cough in children but is frequently missed.Unrecognized children often cycle through repeat asthma treatment, short antibiotic courses that do not address the infection, or open-ended reassurance without further evaluation.This review summarizes the clinical presentation, diagnostic criteria, differential diagnosis, treatment, and follow-up of PBB in children.We conducted a targeted narrative review (PubMed, through September 2026) of clinical trials, longitudinal studies, systematic reviews, and professional-society guidance, distinguishing evidence for antibiotic treatment from limited observational evidence linking recurrent PBB to bronchiectasis.Clinicians should suspect PBB in a child with a daily wet cough lasting more than four weeks and no findings indicating another cause.Resolution after an appropriate antibiotic course supports the diagnosis.Amoxicillinclavulanate remains the usual first-line treatment, typically for two weeks initially, with reassessment and selective extension to four weeks if the child has not cleared.Further investigation is warranted when symptoms persist despite adequate treatment, recurrence is frequent, or specific warning signs appear.In an otherwise typical, treatment-responsive case, bronchoscopy and chest computed tomography (CT) are not routine first steps.Management hinges on recognizing the wet-cough phenotype, giving an adequate therapeutic trial, confirming resolution, and investigating promptly when treatment fails.Antibiotics appear to improve cough resolution, but this rests on a small number of trials with limited certainty, and evidence that treatment itself prevents bronchiectasis remains thin.
Tavapadon is an oral, once-daily, non-catechol partial agonist selective for the D1 and D5 dopamine receptors and represents a mechanistically distinct option currently under clinical investigation for Parkinson disease (PD). This narrative review critically evaluates the biological rationale for D1/D5 receptor targeting, the pharmacological and preclinical development of tavapadon, and the accumulating phase 1–3 clinical evidence for its use as monotherapy in early PD and as adjunctive therapy in patients with motor fluctuations, while highlighting remaining evidence gaps and methodological limitations. A non-systematic literature search of PubMed/MEDLINE, Embase, ClinicalTrials.gov , and Scopus (through May 2026) was performed to identify representative and pivotal randomized controlled trials, pharmacokinetic/pharmacodynamic studies, and mechanistic preclinical investigations relevant to tavapadon and D1/D5 receptor agonism; this narrative approach was not intended to be exhaustive or fully reproducible in the manner of a systematic review. Mechanistically, selective stimulation of the direct striatal pathway together with submaximal intrinsic efficacy at the D1 receptor has been proposed, as a mechanistic hypothesis rather than a demonstrated clinical mechanism, to preserve antiparkinsonian benefit while limiting the receptor-signaling intensity implicated in levodopa-induced dyskinesia. In the phase 2 PARKWAY-II study and the now fully published phase 3 TEMPO-1 and TEMPO-2 trials, fixed- and flexible-dose tavapadon produced clinically meaningful improvements in MDS-UPDRS motor scores compared with placebo in early PD, and in the phase 3 TEMPO-3 trial, adjunctive tavapadon significantly increased daily good ON time and reduced OFF time in levodopa-treated patients with motor fluctuations; efficacy in all trials has been demonstrated only against placebo, with no head-to-head data against levodopa or other dopamine agonists. Adverse events were more frequent with tavapadon than placebo (approximately 72–76% versus 55% across TEMPO-2 and TEMPO-3), with nausea, headache, and dizziness the most common; no excess signal of impulse-control disorders relative to placebo was detected over the available 26–27-week controlled treatment period, and no clinically significant QTc prolongation was observed. The 58-week open-label TEMPO-4 extension, now reported in a peer-reviewed AAN abstract publication in Neurology alongside earlier interim conference data, suggests sustained benefit and a stable long-term levodopa requirement, but lacks a randomized control and cannot yet establish long-term safety superiority over existing agents. Tavapadon is a mechanistically novel candidate with preliminary evidence of efficacy; its ultimate clinical utility will depend on head-to-head trials and long-term safety data.
American Journal of Pediatrics · مجلد 12 (3) · 87-102
Background: Parapneumonic effusion (PPE) and empyema remain serious complications of childhood pneumonia associated with significant morbidity despite advances in antimicrobial therapy and surgical techniques. Accurate disease staging and timely stage-directed intervention are fundamental to optimal outcomes. Objective: To provide a current, evidence-based synthesis of the definition, etiology, diagnosis, and management of complicated pneumonia in children, with particular focus on areas of ongoing clinical controversy. Methods: A narrative review incorporating randomized controlled trials, systematic reviews, meta-analyses, Cochrane reviews, and international clinical guidelines published between 2016 and 2026 was conducted. PubMed was searched through May 2026 using terms including pneumonia, complicated pneumonia, parapneumonic effusion, empyema, VATS, fibrinolysis, decortication, and pediatric. Results: Chest radiography remains the initial imaging modality for suspected complicated pneumonia, with lateral decubitus views needed to assess pleural fluid mobility. However, chest ultrasonography is the preferred imaging modality for evaluating parapneumonic effusions and empyema because of its superior diagnostic accuracy, ability to characterize pleural collections, and absence of ionizing radiation. Management is stage-dependent, combining targeted antibiotic therapy with procedural intervention when indicated. Image-guided pigtail catheter drainage with intrapleural fibrinolytic therapy is effective for most patients. VATS demonstrates particular utility during the fibrinopurulent stage. No single fibrinolytic agent has demonstrated clear superiority; however, tissue plasminogen activator is most widely employed. Open decortication remains reserved for refractory or advanced-stage disease. Conclusion: Early diagnosis, appropriate antibiotics, and prompt intervention or surgery are all important for optimal care. The optimal outcomes require a multidisciplinary, individualized, stage-directed approach. Interventional radiology is appropriate for single loculations, while early VATS is favored for thick pleural rind or multiple loculations. Further high-quality prospective research is needed to establish definitive treatment algorithms.
Background: Human papillomavirus (HPV) is a leading cause of cervical cancer and other HPV-related cancers globally. Vaccination against HPV has proven to be a pivotal intervention in reducing the burden of these diseases. However, questions remain regarding long-term efficacy, dosing strategies, and real-world outcomes of HPV vaccines. Objective: We aim to synthesise evidence from randomised controlled trials and long-term follow-up studies on the efficacy, immunogenicity, safety, and real-world impact of HPV vaccines. Methodology: A comprehensive search was conducted in PubMed, Cochrane Library, Embase, Scopus, and Web of Science for studies published in English from 2019 to 2024. Eligible studies included randomised controlled trials and long-term follow-up analyses focusing on HPV vaccine efficacy, dosing regimens, and population-specific outcomes. Data were extracted and synthesised narratively, with findings organised into five thematic areas. Results: Seventeen studies met the inclusion criteria. Findings confirm the high efficacy of HPV vaccines in preventing HPV-related cancers and precancers, with durable immunogenicity observed up to 12 years post-vaccination. Evidence supports the potential of single-dose regimens, which could improve accessibility in resource-limited settings. Real-world data demonstrated significant reductions in HPV-related diseases across diverse populations, reinforcing the global impact of HPV vaccination programs. Conclusion: This review highlights the critical role of HPV vaccines in reducing the burden of HPV-related cancers, with robust efficacy, long-term protection, and favourable safety profiles. The findings underscore the need for continued research into optimised vaccination strategies and the expansion of global vaccination efforts.
HPV vaccinationhuman papillomaviruscervical cancer preventionHPV-associated cancers
Journal of Advanced Trends in Medical Research · مجلد 2 (4) · 671-681
Hair loss, or alopecia, encompasses a diverse range of conditions including both cicatricial (scarring) and non-cicatricial (non-scarring) forms, with significant implications for patients’ physical appearance, psychological well-being and overall quality of life. The limitations of traditional therapies such as topical agents, oral medications and hair transplantation have led to increasing interest in regenerative approaches. Amongst these, platelet-rich plasma (PRP) and exosome-based therapies have emerged as promising biologic interventions. PRP, derived from autologous blood, contains a high concentration of platelets rich in growth factors that support hair follicle regeneration, angiogenesis and cellular proliferation. Evidence suggests its potential benefits in various types of hair loss particularly androgenetic alopecia, alopecia areata and telogen effluvium, although standardised protocols, optimal dosing and long-term outcomes remain uncertain. Exosomes are small extracellular vesicles secreted by stem cells that offer a novel cell-free alternative capable of delivering complex molecular signals to modulate inflammation, stimulate follicular stem cells, and promote dermal remodeling. Early findings indicate possible applications across a range of alopecias including chemotherapy-induced hair loss, autoimmune related alopecia and structural hair shaft disorders such as trichorrhexis nodosa and monilethrix. This narrative review provides an updated overview of PRP and exosome-based therapies, outlining their mechanisms of action, clinical applications and current limitations. While both modalities show therapeutic promise, their biologic variability, lack of regulatory standardisation and need for comparative trials highlight critical gaps in evidence. Further research is warranted to establish reproducible treatment protocols and determine long-term efficacy and safety for clinical use.
Background: Medication turnaround time (TAT) is a critical metric for evaluating the efficiency and safety of hospital pharmacy operations. Optimizing TAT is essential to ensure patient safety, reduce medication errors, enhance workflow efficiency, enhance resource utilization and enhance both the continuity of care and patient satisfaction. Aim: To discuss the important of TAT, factors influencing medication TAT and provide evidence-based recommendations to optimize medication delivery thereby improve patient care. Methods: A comprehensive search of PubMed, Google Scholar, and ScienceDirect was conducted up to June 15, 2025. Eligible studies included if they were conducted in inpatient settings and reported medication TAT as outcome. Outpatient studies and those without relevant data were excluded. Data on study characteristics, interventions, and outcomes were extracted and summarized narratively; no meta-analysis was performed due to the heterogeneity of the studies. Results: Analysis identified several determinants of prolonged TAT included inefficient health IT systems, inadequate communication, staffing limitations, and inconsistent workflows. Effective interventions encompassed automation, workflow redesign, staff role optimization, and process standardization. These strategies consistently reduced TAT, with reported improvements of 10% to over 50%. Conclusion: TAT is a fundamental indicator to measure hospital pharmacy performance and improve patient outcomes. Addressing the barriers through evidence-based strategies can significantly streamline the medication use process. Optimizing medication TAT requires a multifaceted approach that include integrates technology, standardized workflows, and improve human factors. Evidence suggests these approaches not only enhance operational efficiency but also reduce errors, strengthen regulatory compliance, and ultimately improve patient safety as well as satisfaction.
In the existing effort, a dataset of 309 experimentally screened molecules for in vitro (Ki) agonist potential for Prostaglandin E2 (PGE2) receptor 2 subtype (EP2), which is a metabolite of arachidonic acid that binds with and regulates cellular responses to PGE2, was investigated in the QSAR (Quantitative structure–activity relationship) study. A six-parameter QSAR model was developed that meets the specified values for internal and external validation as well as random parameters such as R2tr = 0.808, Q2LMO = 0.794, R2ex = 0.781. Insightful and quantitative opinion reveals several underappreciated and distinct structural features that are responsible for the agonist potency of these molecules on Prostaglandin EP2 receptor such as; the hydrogen atom is correct 2 bonds from the donor atom, the sp2 hybridized carbon atom is correct 2 bonds from the cyclic nitrogen atom, and so on. The developed QSAR model captures the narrative as well as the novel pharmacophoric features. The QSAR effect was further demonstrated using the reported crystalline buildings of CP533536 with the Prostaglandin EP2 receptor activity. The evaluation led to the identification of valuable new pharmacophoric properties that will be used to optimize lead compounds in the future.
Advances in Medical Education and Practice · مجلد Volume 15 · 487-500
Purpose: Basic medical sciences are of a solid abstract nature. Pharmacology is a challenging discipline delivered in all healthcare-related curricula with different aims and goals. Memes are one of aiding instructional designs proved to surge students’ performance and satisfaction with the educational process. Apart from assessing medical students’ and faculty’s perception of meme use in pharmacology learning, the current study aimed to explore the criteria of preferences and factors associated with successful memes’ adoption in this discipline as one of the most challenging basic medical sciences. Methods: A biphasic study was conducted among second-year undergraduate medical students and faculty members. The study involved assessing the perceptions of staff and students, and thematic content analysis was performed on the narrative responses of the participants to explore factors contributing to the success of learning memes. Additionally, students’ performance was also analyzed. Results: The use of memes in pharmacology was well perceived by medical students, with a mean satisfaction rating of 4.5/5 for high-achieving students and 4.33 for low-achieving students. Memes were associated with a performance surge ( p = 0.022). Six themes emerged as criteria for a successful learning experience of meme use: previous scientific background on the meme topic, scenario context of the meme, learning concepts tackled by memes, the simplicity of meme’s message, the relevance of meme’s message to practice, and the modality of meme’s use in the topic of education. Regarding the perception of meme use in pharmacology learning, four themes emerged: the mode and engagement of learning experience mode, the feasibility of meme use in pharmacology learning, students’ attitudes towards further meme inclusion in their study, and the perceived impact of memes on students’ cognitive skills. Conclusion: The use of memes in pharmacology yields positive learning outcomes. A careful selection of memes is required to ensure a successful learning experience. Keywords: Memes, pharmacology education, instructional design, performance, perception
memespharmacology educationbasic medical sciences educationmedical students